Back to discover
Disease

Obesity, Metabolically Benign

Late-stage therapeutic developmentEmerging research
MeSHObesity, Metabolically Benign
1
Publications
24
Clinical trials
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Metabolically Healthy Obesity.

Research2020-05-01Endocrine reviews

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: High
Key developments
  • 6 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Clinical Milestones18View all 18
Results posted 1
Results expected 5
Recently completed 5
Other updates 5
+10 more in the activity timeline below
Activity timeline18

Clinical trials

12 sponsors · 3 new · 6 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weekly

Phase 4 · Active, not recruiting · Novo Nordisk A/S

A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events

Phase 4 · Active, not recruiting · Currax Pharmaceuticals

Effect of Metformin ER With Hypocaloric Diet on Weight Loss in Overweight/Obese Patients With Increased Waist Circumference

Phase 4 · Active, not recruiting · University of California, Los Angeles

A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial

Phase 4 · Active, not recruiting · Mayo Clinic

Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic Assessment

Phase 4 · Active, not recruiting · University of Sao Paulo General Hospital

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Phase 3 · Active, not recruiting · Eli Lilly and Company
Recently completed

Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Phase 2/3 · Completed · Yale University

A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease

Phase 3 · Completed · Eli Lilly and Company

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

Phase 3 · Completed · Eli Lilly and Company

A Randomized, Allocation-concealed, Assessor-blinded, Parallel-group Trial Evaluating the Association Between Erectile Dysfunction and Left Ventricular Diastolic Dysfunction and Comparing the Effects of Tadalafil, SGLT2 Inhibitors, and Their Combination in Patients With Metabolic Syndrome.

Phase 4 · Completed · Kafrelsheikh University

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)

Phase 3 · Completed · Eli Lilly and Company

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)

Phase 3 · Completed · Eli Lilly and Company

Evidence coverage

8 treatments

How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.

Partial evidence coverage
52% · 124/240 eligible items incorporated

Largest gap: off claim endpoint family (8, endpoint-family).

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Metabolically Healthy Obesity.

Endocrine reviews · 2020 · 663 cites
Recent publications

Metabolically Healthy Obesity.

Endocrine reviews · 2020 · 663 cites
Leading journals1
  • Endocrine reviews1
Leading researchers1
  • Blüher M1
Affiliations (unnormalised)1
  • University of Leipzig1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A sub-PHENOTYPE of obese individuals who have a risk for CARDIOVASCULAR DISEASES between that of healthy individuals with normal weight and unhealthy individuals with obesity.

Identifiers
MeSHObesity, Metabolically Benign
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.